Objective: To compare the efficacy of meloxicam and a glucosamine-chondroitin (Glu-Ch) supplement in the management of feline osteoarthritis (OA).
Methods: Prospective, blinded, randomized clinical trial. Cats over eight years of age with clinical signs of chronic OA were assigned to one of two groups and Glu-Ch or meloxicam was administered orally for 70 days, followed by a placebo until day 98. Cats were assessed by a veterinarian on five occasions and the owner completed an assessment form at the same time.
Results: Data were collected from thirty cats. Pre-treatment disease scores were significantly higher in the meloxicam group for owner mobility (p=0.01) and veterinary lameness (p=0.02). Owner mobility scores at day 14 (p=0.01) and day 42 (p=0.002) were significantly improved compared to pre-treatment scores for the meloxicam group. When meloxicam and Glu-Ch were discontinued and the placebo commenced, a significant proportion of the meloxicam group showed worsening of all the owner-assessed scores between day 70 and day 98, when compared to the Glu-Ch group (mobility p=0.01; activity p=0.02; temperament p=0.04; lifestyle p=0.01).
Conclusions: Treatment with meloxicam resulted in a significant improvement in mobility and activity levels of cats with OA until the placebo was introduced. A greater proportion of cats receiving meloxicam medication showed a significant worsening of owner assessment scores once the placed was introduced, when compared to the Glu-Ch group.
Keywords: Feline; chondroitin; glucosamine; meloxicam; osteoarthritis.